Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/clot-blog Cardiologist and professor, Dr Samuel Goldhaber, Harvard Medical School and Brigham and Women's Hospital, animates this forum on venous thromboembolism and anticoagulation management. en-us theheart.org theheart.org info@theheart.org http://blogs.theheart.org/images/clot-blog/rss_banner_url.jpg Cardiologist and professor, Dr Samuel Goldhaber, Harvard Medical School and Brigham and Women's Hospital, animates this forum on venous thromboembolism and anticoagulation management. http://blogs.theheart.org/clot-blog IVC filters: The genie's out of the bottle Clotblog with Dr Samuel Goldhaber info@theheart.org The placement of inferior vena cava (IVC) filters has grown exponentially in the US, with up to 20% of these being placed in inappropriate patients.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/psl3Idt2rLw" height="1" width="1"/> The placement of inferior vena cava (IVC) filters has grown exponentially in the US, with up to 20% of these being placed in inappropriate patients. As we balance the benefit vs risk for this procedure and evaluate cost, Dr Paul Stein's proposed randomized trial will help us to see more clearly.

See also:

Stein PD, Matta F, Huss RD. Increasing use of vena cava filters for prevention of pulmonary embolism. Am J Med 2011; 124:655-661. Abstract.

]]> Fri, 03 Feb 2012 08:30:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/psl3Idt2rLw/ivc-filters-the-genie-s-out-of-the-bottle http://blogs.theheart.org/clot-blog/2012/2/2/ivc-filters-the-genie-s-out-of-the-bottle http://blogs.theheart.org/clot-blog/2012/2/2/ivc-filters-the-genie-s-out-of-the-bottle#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/ivc-filters-the-genie-s-out-of-the-bottle.jpg 0 http://blogs.theheart.org/clot-blog/2012/2/2/ivc-filters-the-genie-s-out-of-the-bottle Emergency hospitalization from adverse drug events: Warfarin the biggest culprit Clotblog with Dr Samuel Goldhaber info@theheart.org In the US warfarin is by far the greatest cause of adverse drug events leading to emergency hospitalization.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/hOgHeZi-gRw" height="1" width="1"/> In the US warfarin is by far the greatest cause of adverse drug events leading to emergency hospitalization. This is another reason to ensure that patients are following the most appropriate anticoagulation regimen and that they are closely followed for safety.

See also:

Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans.  N ngl J Med 2011; 365:2002-2012. Abstract.

Warfarin tops list for emergency hospitalizations in seniors

 

]]> Fri, 27 Jan 2012 08:50:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/hOgHeZi-gRw/emergency-hospitalization-from-adverse-drug-events-warfarin-the-biggest-culprit http://blogs.theheart.org/clot-blog/2012/1/26/emergency-hospitalization-from-adverse-drug-events-warfarin-the-biggest-culprit http://blogs.theheart.org/clot-blog/2012/1/26/emergency-hospitalization-from-adverse-drug-events-warfarin-the-biggest-culprit#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/emergency-hospitalization-from-adverse-drug-events-warfarin-the-biggest-culprit.jpg 0 http://blogs.theheart.org/clot-blog/2012/1/26/emergency-hospitalization-from-adverse-drug-events-warfarin-the-biggest-culprit Self-monitoring INR and self-managing warfarin to reduce thromboembolic events Clotblog with Dr Samuel Goldhaber info@theheart.org A recent study published in the Lancet reports a 50% reduction in thromboembolic events among patients who self-monitor their INR and self-manage their warfarin dosing. Why aren't these practices more common?<img src="http://feeds.feedburner.com/~r/clot-blog/~4/sh0IL99G4MM" height="1" width="1"/> A recent study published in the Lancet reports a 50% reduction in thromboembolic events among patients who self-monitor their INR and self-manage their warfarin dosing. Why aren't these practices more common?

See also:

Anticoagulation self-monitoring halves thromboembolic risk  

Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data.  Lancet 2011; DOI:10.1016/S0140-6736(11)61294-4. Abstract.

]]> Fri, 20 Jan 2012 07:30:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/sh0IL99G4MM/selfmonitoring-inr-and-selfmanaging-warfarin-to-reduce-thromboembolic-events http://blogs.theheart.org/clot-blog/2012/1/18/selfmonitoring-inr-and-selfmanaging-warfarin-to-reduce-thromboembolic-events http://blogs.theheart.org/clot-blog/2012/1/18/selfmonitoring-inr-and-selfmanaging-warfarin-to-reduce-thromboembolic-events#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/selfmonitoring-inr-and-selfmanaging-warfarin-to-reduce-thromboembolic-events.jpg 4 http://blogs.theheart.org/clot-blog/2012/1/18/selfmonitoring-inr-and-selfmanaging-warfarin-to-reduce-thromboembolic-events LIFENOX: No advantage of VTE prophylaxis in hospitalized medical service patients Clotblog with Dr Samuel Goldhaber info@theheart.org The surprising results of the LIFENOX trial--which failed to show an advantage of daily enoxaparin vs placebo to reduce mortality in the acute-care setting--challenge dogma. What explains these results?<img src="http://feeds.feedburner.com/~r/clot-blog/~4/9dbZqSZ5uc0" height="1" width="1"/> The surprising results of the LIFENOX trial—which failed to show an advantage of daily enoxaparin vs placebo to reduce mortality in the acute-care setting—challenge dogma. What explains these results?

See also:

Kakkar AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2012; 365:2463-2472. Abstract.

Enoxaparin prophylaxis doesn't cut mortality in acute-care setting

]]> Fri, 13 Jan 2012 09:20:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/9dbZqSZ5uc0/lifenox-no-advantage-of-vte-prophylaxis-in-hospitalized-medical-service-patients http://blogs.theheart.org/clot-blog/2012/1/9/lifenox-no-advantage-of-vte-prophylaxis-in-hospitalized-medical-service-patients http://blogs.theheart.org/clot-blog/2012/1/9/lifenox-no-advantage-of-vte-prophylaxis-in-hospitalized-medical-service-patients#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/lifenox-no-advantage-of-vte-prophylaxis-in-hospitalized-medical-service-patients.jpg 1 http://blogs.theheart.org/clot-blog/2012/1/9/lifenox-no-advantage-of-vte-prophylaxis-in-hospitalized-medical-service-patients Focus on pulmonary arterial hypertension and the right ventricle at the Cardiology Society of Mexico Clotblog with Dr Samuel Goldhaber info@theheart.org Focus on pulmonary arterial hypertension and the right ventricle at the Cardiology Society of Mexico<img src="http://feeds.feedburner.com/~r/clot-blog/~4/Xvq35KiTLEM" height="1" width="1"/> Dr Samuel Goldhaber recently sat down with Dr Julio Sandoval to discuss the challenges and rewards of coordinating the scientific committee at the recent Cardiology Society of Mexico annual meeting in Puerto Vallarta.

To read an English-language translation of this Spanish discussion, click here.

]]> Fri, 06 Jan 2012 09:10:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/Xvq35KiTLEM/focus-on-pulmonary-arterial-hypertension-and-the-right-ventricle-at-the-cardiology-society-of-mexico http://blogs.theheart.org/clot-blog/2011/12/23/focus-on-pulmonary-arterial-hypertension-and-the-right-ventricle-at-the-cardiology-society-of-mexico http://blogs.theheart.org/clot-blog/2011/12/23/focus-on-pulmonary-arterial-hypertension-and-the-right-ventricle-at-the-cardiology-society-of-mexico#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/focus-on-pulmonary-arterial-hypertension-and-the-right-ventricle-at-the-cardiology-society-of-mexico.jpg 0 http://blogs.theheart.org/clot-blog/2011/12/23/focus-on-pulmonary-arterial-hypertension-and-the-right-ventricle-at-the-cardiology-society-of-mexico Celebrating 75-years of the Cardiology Society of Mexico with Dr Carlos Martínez Sánchez Clotblog with Dr Samuel Goldhaber info@theheart.org As the Cardiology Society of Mexico celebrated an important anniversary in Puerto Vallarta, Dr Samuel Goldhaber caught up with the society's president. Find out about the society, its constituents, and regional challenges.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/wnLtyd4R6SQ" height="1" width="1"/> As the Cardiology Society of Mexico celebrated an important anniversary in Puerto Vallarta, Dr Samuel Goldhaber caught up with the society's president. Find out about the society, its constituents, and regional challenges.

To read an English-language translation of this Spanish discussion, click here.

]]> Fri, 23 Dec 2011 08:00:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/wnLtyd4R6SQ/celebrating-75years-of-the-cardiology-society-of-mexico-with-dr-carlos-martnez-snchez http://blogs.theheart.org/clot-blog/2011/12/19/celebrating-75years-of-the-cardiology-society-of-mexico-with-dr-carlos-martnez-snchez http://blogs.theheart.org/clot-blog/2011/12/19/celebrating-75years-of-the-cardiology-society-of-mexico-with-dr-carlos-martnez-snchez#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/celebrating-75years-of-the-cardiology-society-of-mexico-with-dr-carlos-martnez-snchez.jpg 0 http://blogs.theheart.org/clot-blog/2011/12/19/celebrating-75years-of-the-cardiology-society-of-mexico-with-dr-carlos-martnez-snchez Vitamin T and other concerns in Mexican pediatric cardiology with Dr Carlos Zabal Clotblog with Dr Samuel Goldhaber info@theheart.org From the recent annual meeting of the Mexican Cardiology Society, Dr Samuel Goldhaber discusses patent ductus arteriosus, aortic-valve stenosis, and the growing issue of vitamin T overconsumption with Mexican pediatric cardiologist Dr Carlos Zabal.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/AH2SsViKdSw" height="1" width="1"/> From the recent annual meeting of the Mexican Cardiology Society, Dr Samuel Goldhaber discusses patent ductus arteriosus, aortic-valve stenosis, and the growing issue of "vitamin T" overconsumption with Mexican pediatric cardiologist Dr Carlos Zabal.

To read an English-language translation of this Spanish discussion, click here.

]]> Fri, 16 Dec 2011 08:25:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/AH2SsViKdSw/vitamin-t-and-other-concerns-in-mexican-pediatric-cardiology-with-dr-carlos-zabal http://blogs.theheart.org/clot-blog/2011/12/15/vitamin-t-and-other-concerns-in-mexican-pediatric-cardiology-with-dr-carlos-zabal http://blogs.theheart.org/clot-blog/2011/12/15/vitamin-t-and-other-concerns-in-mexican-pediatric-cardiology-with-dr-carlos-zabal#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/vitamin-t-and-other-concerns-in-mexican-pediatric-cardiology-with-dr-carlos-zabal.jpg 0 http://blogs.theheart.org/clot-blog/2011/12/15/vitamin-t-and-other-concerns-in-mexican-pediatric-cardiology-with-dr-carlos-zabal Got your Green Book? Clotblog with Dr Samuel Goldhaber info@theheart.org Edited by Marc Sabatine, Pocket Medicine, 4th ed (aka "the Green Book") is a must-have for virtually all healthcare professionals. Its extensive references, organization by subspecialties, algorithms, and photo inserts make it immensely practical.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/SFml4BGcioc" height="1" width="1"/> Edited by Marc Sabatine, Pocket Medicine, 4th ed (aka "the Green Book") is a must-have for virtually all healthcare professionals. Its extensive references, organization by subspecialties, algorithms, and photo inserts make it immensely practical and easy to use.

Do you carry the Green Book or the Washington Manual? Or both?

]]> Mon, 12 Dec 2011 15:05:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/SFml4BGcioc/got-your-green-book http://blogs.theheart.org/clot-blog/2011/12/6/got-your-green-book http://blogs.theheart.org/clot-blog/2011/12/6/got-your-green-book#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/got-your-green-book.jpg 0 http://blogs.theheart.org/clot-blog/2011/12/6/got-your-green-book ACP's new inpatient VTE prophylaxis guidelines: Radical or right-on? Clotblog with Dr Samuel Goldhaber info@theheart.org Following an extensive analysis of the literature, the American College of Physicians has concluded that the administration of prophylaxis to prevent DVT and pulmonary embolism has not resulted in a decrease in mortality.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/iTzzcfx1N0M" height="1" width="1"/> Following an extensive analysis of the literature, the American College of Physicians has concluded that the administration of prophylaxis to prevent DVT and pulmonary embolism has not resulted in a decrease in mortality. Based on these surprising (and disappointing) results, the ACP's new guidelines judge that pharmacological VTE prophylaxis is appropriate only in moderate and high risk patients and that it should not be administered by default to all.

What are your thoughts? Are these new guidelines radical or right-on?

See also:

Lederle FA, Zylla D, MacDonald R et al. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: A background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2011.155:602-615. Available here.

Qaseem A, Chou R, Humphrey LL et al. Venous thromboembolism prophylaxis in hospitalized patients: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2011: 625-632. Available here. 

Baker DW, Qaseem A. Evidence-based performance measures: Preventing unintended consequences of quality measurement. Ann Intern Med 2011 155:638-640. Available here.

]]> Fri, 02 Dec 2011 10:30:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/iTzzcfx1N0M/acp-s-new-inpatient-vte-prophylaxis-guidelines-radical-or-righton http://blogs.theheart.org/clot-blog/2011/11/25/acp-s-new-inpatient-vte-prophylaxis-guidelines-radical-or-righton http://blogs.theheart.org/clot-blog/2011/11/25/acp-s-new-inpatient-vte-prophylaxis-guidelines-radical-or-righton#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/acp-s-new-inpatient-vte-prophylaxis-guidelines-radical-or-righton.jpg 1 aha 2011 aha 2011 http://blogs.theheart.org/clot-blog/2011/11/25/acp-s-new-inpatient-vte-prophylaxis-guidelines-radical-or-righton Anticoagulation bridging: An update for practitioners Clotblog with Dr Samuel Goldhaber info@theheart.org Does your patient need to be bridged? Will bridging with low-molecular-weight heparin suffice? Does your patient require bridging in the hospital setting? Find out more.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/4NrT6fayfwQ" height="1" width="1"/> Does your patient need to be bridged? Will bridging with low-molecular-weight heparin suffice? Does your patient require bridging in the hospital setting? Find out more.

 

To download Dr Goldhaber's presentation on bridging at the AHA 2011, click here.

 

See also:

"Bridging" anticoagulation may not be necessary in vast majority of patients

When to bridge patients on long-term anticoagulation

]]> Fri, 25 Nov 2011 11:30:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/4NrT6fayfwQ/anticoagulation-bridging-an-update-for-practitioners http://blogs.theheart.org/clot-blog/2011/11/24/anticoagulation-bridging-an-update-for-practitioners http://blogs.theheart.org/clot-blog/2011/11/24/anticoagulation-bridging-an-update-for-practitioners#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/anticoagulation-bridging-an-update-for-practitioners.jpg 2 aha 2011 aha 2011 http://blogs.theheart.org/clot-blog/2011/11/24/anticoagulation-bridging-an-update-for-practitioners Extended VTE prophylaxis after hospital discharge: Lessons from ADOPT Clotblog with Dr Samuel Goldhaber info@theheart.org The ADOPT trial is another chapter in the scientific discourse on VTE prophylaxis and will help move science forward if we study the results closely and regroup to use new study information wisely.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/iXUfLHIp024" height="1" width="1"/> The ADOPT trial is another chapter in the scientific discourse on VTE prophylaxis and will help move science forward if we study the results closely and regroup to use new study information wisely.

 

To view a summary slideset from the ADOPT trial, click here.

 

See also:

ADOPT: Extended apixaban no better than standard enoxaparin for VTE in medically ill

]]> Tue, 15 Nov 2011 15:55:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/iXUfLHIp024/extended-vte-prophylaxis-after-hospital-discharge-lessons-from-adopt http://blogs.theheart.org/clot-blog/2011/11/15/extended-vte-prophylaxis-after-hospital-discharge-lessons-from-adopt http://blogs.theheart.org/clot-blog/2011/11/15/extended-vte-prophylaxis-after-hospital-discharge-lessons-from-adopt#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/extended-vte-prophylaxis-after-hospital-discharge-lessons-from-adopt.jpg 0 aha 2011 aha 2011 http://blogs.theheart.org/clot-blog/2011/11/15/extended-vte-prophylaxis-after-hospital-discharge-lessons-from-adopt Practicing medicine in a multilingual environment Clotblog with Dr Samuel Goldhaber info@theheart.org As society becomes increasingly multicultural, it's essential to have means—such as a translational telephone—to communicate with patients who speak different languages.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/Gb0vopEpYe0" height="1" width="1"/> As society becomes increasingly multicultural, it's essential to have means—such as a translation service offered via telephone—to communicate with patients who speak different languages.

How have you bridged language barriers with your patients?

]]> Fri, 11 Nov 2011 14:10:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/Gb0vopEpYe0/practicing-medicine-in-a-multilingual-environment http://blogs.theheart.org/clot-blog/2011/11/10/practicing-medicine-in-a-multilingual-environment http://blogs.theheart.org/clot-blog/2011/11/10/practicing-medicine-in-a-multilingual-environment#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/practicing-medicine-in-a-multilingual-environment.jpg 0 http://blogs.theheart.org/clot-blog/2011/11/10/practicing-medicine-in-a-multilingual-environment Aspirin for stroke prevention in AF: More risk than benefit? Clotblog with Dr Samuel Goldhaber info@theheart.org On the heels of a large Danish cohort study that indicated that aspirin had little effect in stroke prevention for patients with atrial fibrillation and with the rise of promising novel anticoagulants, what role is there for aspirin as an agent to prevent<img src="http://feeds.feedburner.com/~r/clot-blog/~4/R2WdrFfn31M" height="1" width="1"/> On the heels of a large Danish cohort study that indicated that aspirin had little effect in stroke prevention for patients with atrial fibrillation and with the rise of promising novel anticoagulants, what role is there for aspirin as an agent to prevent stroke?

See also:

Aspirin should not be used for stroke prevention in AF patients

Olesen JB, Lip GYH, Lindardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106:739-749. Abstract.

]]> Fri, 04 Nov 2011 15:50:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/R2WdrFfn31M/aspirin-for-stroke-prevention-in-af-more-risk-than-benefit http://blogs.theheart.org/clot-blog/2011/11/3/aspirin-for-stroke-prevention-in-af-more-risk-than-benefit http://blogs.theheart.org/clot-blog/2011/11/3/aspirin-for-stroke-prevention-in-af-more-risk-than-benefit#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/aspirin-for-stroke-prevention-in-af-more-risk-than-benefit.jpg 1 http://blogs.theheart.org/clot-blog/2011/11/3/aspirin-for-stroke-prevention-in-af-more-risk-than-benefit What's your QThrombosis risk score? Clotblog with Dr Samuel Goldhaber info@theheart.org Developed by a team of statisticians and epidemiologists and based on a derivation cohort of 2.4 million patients and a validation cohort of 1.2 million patients, the QThrombosis score seeks to quantify the risk of developing venous thromboembolism (VTE).<img src="http://feeds.feedburner.com/~r/clot-blog/~4/oJMAZOKHzC4" height="1" width="1"/> Developed by a team of statisticians and epidemiologists and based on a derivation cohort of 2.4 million patients and a validation cohort of 1.2 million patients, the QThrombosis score seeks to quantify the risk of developing venous thromboembolism (VTE).

Have you used the QThrombosis score? Is the quantification of the risk useful to you and your patients?

See also:

http://www.qthrombosis.org/

Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: Prospective cohort study. BMJ 2011;343:d4656. Abstract.

]]> Fri, 28 Oct 2011 09:15:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/oJMAZOKHzC4/what-s-your-qthrombosis-risk-score http://blogs.theheart.org/clot-blog/2011/10/26/what-s-your-qthrombosis-risk-score http://blogs.theheart.org/clot-blog/2011/10/26/what-s-your-qthrombosis-risk-score#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/what-s-your-qthrombosis-risk-score.jpg 0 http://blogs.theheart.org/clot-blog/2011/10/26/what-s-your-qthrombosis-risk-score Reversing rivaroxaban with prothrombin complex concentrate Clotblog with Dr Samuel Goldhaber info@theheart.org Although tiny in scale, the results of a Dutch study that show that prothrombin complex concentrate (PCC) may reverse the hematological effects of rivaroxaban are exciting and promising.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/lVlrbCdnVnA" height="1" width="1"/> Although tiny in scale, the results of a Dutch study that show that prothrombin complex concentrate (PCC) may reverse the hematological effects of rivaroxaban are exciting and promising.

What are your thoughts?

See also:

  • Possible rivaroxaban antidote identified
  • Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. Circulation 2011; 124:1573-1579. Abstract.
  • Battinelli EM. Reversal of new oral anticoagulants. Circulation 2011; 124:1508-1510. Abstract.

 

]]> Fri, 21 Oct 2011 09:15:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/lVlrbCdnVnA/reversing-rivaroxaban-with-prothrombin-complex-concentrate http://blogs.theheart.org/clot-blog/2011/10/20/reversing-rivaroxaban-with-prothrombin-complex-concentrate http://blogs.theheart.org/clot-blog/2011/10/20/reversing-rivaroxaban-with-prothrombin-complex-concentrate#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/reversing-rivaroxaban-with-prothrombin-complex-concentrate.jpg 0 http://blogs.theheart.org/clot-blog/2011/10/20/reversing-rivaroxaban-with-prothrombin-complex-concentrate Aspirin as VTE prophylaxis for total hip and knee replacement? Clotblog with Dr Samuel Goldhaber info@theheart.org The plot thickens as opposing camps-the American Association of Orthopaedic Surgeons (AAOS) and the American College of Chest Physicians (ACCP)--appear to swap positions on the appropriateness of aspirin for venous thromboembolism prophylaxis in high-risk<img src="http://feeds.feedburner.com/~r/clot-blog/~4/1KaHpx-S1OU" height="1" width="1"/> The plot thickens as proponents of opposing guidelines—the American Association of Orthopaedic Surgeons (AAOS) and the American College of Chest Physicians (ACCP)—appear to swap positions on the appropriateness of aspirin for venous thromboembolism prophylaxis in high-risk orthopedic surgery.

What are your thoughts?      

See also:

  • Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: What are the implications for clinicians and patients? Chest 2009; 135:513-20. Available here.

 

  • Guideline on preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. American Association of Orthopaedic Surgeons. 2011. Available here.

 

  • Pulmonary Embolism Prevention (PEP) trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355:1295-302. Abstract.

 

  • Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2765-75. Available here.

 

  • Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372:31-39. Abstract.

 

  • Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2776-2786. Available here.

 

  • Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373:1673-1680. Abstract.

 

]]> Fri, 14 Oct 2011 09:20:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/1KaHpx-S1OU/aspirin-as-vte-prophylaxis-for-total-hip-and-knee-replacement http://blogs.theheart.org/clot-blog/2011/10/13/aspirin-as-vte-prophylaxis-for-total-hip-and-knee-replacement http://blogs.theheart.org/clot-blog/2011/10/13/aspirin-as-vte-prophylaxis-for-total-hip-and-knee-replacement#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/aspirin-as-vte-prophylaxis-for-total-hip-and-knee-replacement.jpg 0 http://blogs.theheart.org/clot-blog/2011/10/13/aspirin-as-vte-prophylaxis-for-total-hip-and-knee-replacement Postthrombotic syndrome and chronic venous insuffiency Clotblog with Dr Samuel Goldhaber info@theheart.org Frequently overlooked by cardiologists, postthrombotic syndrome—though nonfatal—is a painful and debilitating condition that sidelines patients and robs them of quality of life.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/H1L3wWZpr4o" height="1" width="1"/> Frequently overlooked by cardiologists, postthrombotic syndrome—though nonfatal—is a painful and debilitating condition that sidelines patients and robs them of quality of life.

Find out more at www.preventpts.org

See:

Kahn SR. The post thrombotic syndrome. Thromb Res 2011;127 (suppl 3):S89-92. Abstract.

]]> Thu, 06 Oct 2011 14:30:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/H1L3wWZpr4o/postthrombotic-syndrome-and-chronic-venous-insuffiency http://blogs.theheart.org/clot-blog/2011/10/6/postthrombotic-syndrome-and-chronic-venous-insuffiency http://blogs.theheart.org/clot-blog/2011/10/6/postthrombotic-syndrome-and-chronic-venous-insuffiency#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/postthrombotic-syndrome-and-chronic-venous-insuffiency.jpg 1 http://blogs.theheart.org/clot-blog/2011/10/6/postthrombotic-syndrome-and-chronic-venous-insuffiency Dr Abraham Verghese on the humanity of medicine Clotblog with Dr Samuel Goldhaber info@theheart.org Following beautifully interwoven themes, locations, and epochs, Cutting for Stone by Dr Abraham Verghese is a deeply rewarding read—even without taking into account the finely described incidence of deep vein thrombosis.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/n8mue0raB8g" height="1" width="1"/> Following beautifully interwoven themes, locations, and epochs, Cutting for Stone by Dr Abraham Verghese is a deeply rewarding read—even without taking into account the finely described incidence of deep vein thrombosis. It's an uplifting novel that shows how people can rise to a challenge and make a difference in society.

Have you been inspired by Abraham Verghese's writing?

See:

 

]]> Fri, 23 Sep 2011 11:15:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/n8mue0raB8g/dr-abraham-verghese-on-the-humanity-of-medicine http://blogs.theheart.org/clot-blog/2011/9/14/dr-abraham-verghese-on-the-humanity-of-medicine http://blogs.theheart.org/clot-blog/2011/9/14/dr-abraham-verghese-on-the-humanity-of-medicine#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/dr-abraham-verghese-on-the-humanity-of-medicine.jpg 0 http://blogs.theheart.org/clot-blog/2011/9/14/dr-abraham-verghese-on-the-humanity-of-medicine Take part in the Thrombosis Summit in Boston on September 24 Clotblog with Dr Samuel Goldhaber info@theheart.org The multidisciplinary one-day summit is sponsored by the nonprofit North American Thrombosis Forum and provides a valuable opportunity to discuss updates in research and treatment of pulmonary embolism, deep vein thrombosis, and antiplatelet therapy.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/p_Jm2ZORx2g" height="1" width="1"/> The multidisciplinary one-day summit is sponsored by the nonprofit North American Thrombosis Forum and provides a valuable opportunity to discuss updates in research and treatment of pulmonary embolism, deep vein thrombosis, and antiplatelet therapy.

Please join us on September 24 in Boston. To find out more about the summit and register, click here.

]]> Wed, 07 Sep 2011 14:10:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/p_Jm2ZORx2g/take-part-in-the-thrombosis-summit-in-boston-on-september-24 http://blogs.theheart.org/clot-blog/2011/9/7/take-part-in-the-thrombosis-summit-in-boston-on-september-24 http://blogs.theheart.org/clot-blog/2011/9/7/take-part-in-the-thrombosis-summit-in-boston-on-september-24#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/take-part-in-the-thrombosis-summit-in-boston-on-september-24.jpg 1 http://blogs.theheart.org/clot-blog/2011/9/7/take-part-in-the-thrombosis-summit-in-boston-on-september-24 Evidence to treat recurrent pericarditis Clotblog with Dr Samuel Goldhaber info@theheart.org Until now there has been no clear evidence-based treatment for recurrent pericarditis. The CORP trial presented at the European Society of Cardiology Congres 2011 and published online in the Annals of Internal Medicine helps to fill the void.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/QIC2arMmfuQ" height="1" width="1"/> Until now there has been no clear evidence-based treatment for recurrent pericarditis. The CORP trial presented at the European Society of Cardiology Congres 2011 and published online in the Annals of Internal Medicine helps to fill the void.

See also:

CORP: Colchicine prevents recurrent pericarditis

Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP). A randomized trial. Ann Intern Med 2011. Available here.

 

]]> Mon, 29 Aug 2011 17:50:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/QIC2arMmfuQ/evidence-for-the-best-approach-to-recurrent-pericarditis http://blogs.theheart.org/clot-blog/2011/8/29/evidence-for-the-best-approach-to-recurrent-pericarditis http://blogs.theheart.org/clot-blog/2011/8/29/evidence-for-the-best-approach-to-recurrent-pericarditis#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/evidence-for-the-best-approach-to-recurrent-pericarditis.jpg 0 ESC 2011 ESC 2011 http://blogs.theheart.org/clot-blog/2011/8/29/evidence-for-the-best-approach-to-recurrent-pericarditis